Brief: Mezzion Pharma Says Conducted Type C Meeting With FDA
11/10/2019 24:58
Oct 10 (Reuters) - Mezzion Pharma Co Ltd 140410.KQ :
* MEZZION PHARMA ANNOUNCES THAT IT HAS CONDUCTED A TYPE C
MEETING
WITH THE FDA REGARDING THE TOP LINE DATA FROM THE FUEL PHASE 3
CLINICAL TRIAL
Source text for Eikon: ID:nPn1scYQva
Further company coverage: 140410.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mezzion Pharma
See all newsBrief: Mezzion Secures Strategic Financing To Support Advancement Of Global Phase 3 Fuel-2 Trial In Fontan Patients
Brief: Mezzion Reports Pre-Ind FDA Feedback On The Development Of Udenafil In Adpkd
Brief: Mezzion Pharmaceuticals Appoints Ridwan Shabsigh As President & Chief Operating Officer
Brief: Mezzion Pharmaceuticals Reaches Key Enrollment Milestone In World's Largest Fontan Clinical Trial
Brief: Mezzion Pharmaceuticals Announces Dr Rahul Rathod As Global Principal Investigator For The Confirmatory Pivotal Phase 3 Trial FUEL-2